Trans Genic Inc. (2342.T)

263.00 +38.00 (+16.89%) As of 10:03AM JST. Market open.

Trans Genic Inc.

2-3-36 Tenjin
Chuo-ku
Fukuoka City 810-0001
Japan
81 9 2288 8470
https://www.transgenic.co.jp

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 236

Key executives

Name	Title	Pay	Exercised	Year born
Kenji Fukunaga	CEO, President & Representative Director	N/A	N/A	1969
Kazuo Watanabe	GM of Accounting & Finance Department and Director	N/A	N/A	1967
Yutaka Funabashi	GM of IR, Corporate Management Office & Information Management Office and Director	N/A	N/A	1973
Shunichi Kitajima	Head of CRO Business Division, GM of Facility Management Office & Director	N/A	N/A	1960

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Trans Genic Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services. It also offers drug efficiency and pharmacological test and safety studies; sugar chain analysis and synthesis services; advice and support services, including M&A, business revitalization, business succession services; and contract production services, such as genetically modified mice, antibodies, protein hypers, and expressing cells, as well as sells mouse-related products and mouse models, and research reagents. The company was formerly known as Kumamoto Immunochemical Laboratories Inc. and changed its name to Trans Genic Inc. in April 2000. Trans Genic Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.

Corporate governance

Trans Genic Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.